Secukinumab: A Biologic To Treat Psoriasis
Il-17 targeting is the new trend in the biologic systemic treatment of psoriasis. Secukinumab:
- is a fully anti-interleukin-17A monoclonal antibody
- is (at the time of publishing this article) the latest Il-17A drug to have exited phase III trials.
The results out of two studies show excellent results (phase 3, double-blind, 52-week trials) FIXTURE and ERASURE studies:
- Secukinumab vs etanercept for a year on 1306 patients, (FIXTURE study) or vs placebo (ERASURE study)
- dose of 300 mg or 150 mg (administered once weekly for 5 weeks, then every 4 weeks)
- vs etanercept at a dose of 50 mg (administered twice weekly for 12 weeks, then once weekly) (FIXTURE study)
- vs placebo (ERASURE study)
- RESULTS (PASI 75 at 12 weeks)
- ERASURE study: 81.6% with 300 mg of secukinumab, 71.6% with 150 mg of secukinumab, and 4.5% with placebo
- FIXTURE study: 77.1% with 300 mg of secukinumab, 67.0% with 150 mg of secukinumab, 44.0% with etanercept, and 4.9% with placebo
- Infections rates were comparable with etanercept
Conclusion: Secukinumab shows promising results in late stage clinical trials and is (at the time of publication) the newest biologic from the pipeline against psoriasis.
These studies are done by Novartis Pharmaceuticals
Dr Christophe Hsu – dermatologist. Geneva, Switzerland
Article selection: Prof Dr Jean-Hilaire Saurat – dermatologist. Geneva, Switzerland
Source of information: Secukinumab in plaque psoriasis–results of two phase 3 trials. Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, Puig L, Nakagawa H, Spelman L, Sigurgeirsson B, Rivas E, Tsai TF, Wasel N, Tyring S, Salko T, Hampele I, Notter M, Karpov A, Helou S, Papavassilis C; ERASURE Study Group; FIXTURE Study Group. N Engl J Med. 2014 Jul 24;371(4):326-38. doi: 10.1056/NEJMoa1314258. Epub 2014 Jul 9.